Anticuerpos contra la cardiolipina en glomerulonefritis postestreptocócica concurrente con anemia hemolítica autoinmunitaria: a propósito de un caso / Anticardiolipin antibodies in concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia: A case report

En este artículo, presentamos el caso de una paciente con glomerulonefritis aguda postestreptocócica (GNAPE) y anemia hemolítica autoinmunitaria (AHAI). Además de los signos típicos de la GNAPE, la paciente tuvo un resultado positivo en la prueba de antiglobulina directa y anticuerpos contra la cardiolipina sin que presentara las manifestaciones clínicas típicas del síndrome antifosfolipídico. Este caso genera dudas respecto de la relación entre el estreptococo y el desarrollo de anemia hemolítica autoinmunitaria en los niños. Este caso destaca la posibilidad de que las infecciones estreptocócicas de nuestra paciente podrían haber causado la anemia, ya sea en el contexto de anticuerpos antifosfolipídicos preexistentes o por haber desencadenado el desarrollo de anticuerpos patogénicos, que luego lleva a la presentación clínica de hemólisis. Se presume que, en la paciente, los anticuerpos contra la cardiolipina inducidos por la infección estreptocócica podrían tener una función directa en la presentación clínica de AHAI.

We present a case of acute post-streptococcal glomerulonephritis (APSGN) with autoimmune hemolytic anemia (AIHA). Along with the classic findings of APSGN, the patient had a positive direct antiglobulin test and an anticardiolipin antibody without any typical clinical manifestations of antiphospholipid syndrome (APS). This case raises questions of the relationship between Streptococcus and the development of autoimmune hemolytic anemia in children. Our case highlights the possibility that the streptococcal infections in this patient might be responsible for her anemia, either in setting of underlying antiphospholipid antibodies, or in having triggered the development of pathogenic antibodies, which subsequently leads to the clinical evolution of hemolysis. It is presumed that in our case, the anticardiolipin antibody induced by streptococcal infection may play a direct role in the clinical evolution of AIHA.

Antiphospholipid syndrome: a clinical and laboratorial challenge / Síndrome do anticorpo antifosfolípide: um desafio clínico e laboratorial

Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by the presence of a heterogeneous family of antibodies that bind to plasma proteins with affinity for phospholipid surfaces. The two major protein targets of antiphospholipid antibodies are prothrombin and β2-glycoprotein I (β2GPI). APS leads to aprothrombotic state, and it is characterized by the occurrence of arterial, venous or microvascular thrombosis or recurrent fetal loss. The diagnosis of APS is based on a set of clinical criteria and the detection of lupus anticoagulant (LA), anticardiolipin antibodies (ACA) or anti-β2GPI in plasma. Although laboratory tests are essential for APS diagnosis, these tests have limitations associated with the robustness, reproducibility and standardization. The standardization of diagnostic tests for detection of APLAs has been a challenge and a variety of results have been obtained using different commercial kits and in-house techniques. An increased sensitivity of the ELISA kits for detection of ACA effectively has contributed to APS diagnosis. However, the lack of specificity associated with a high number of false-positive results is a clinical and laboratorial challenge, since such results may lead to mistaken clinical decisions, such as prescription of oral anticoagulant, leading to the risk of hemorrhaging. Furthermore, clinicians are often unfamiliar with these tests and have difficulty interpreting them, requiring interaction between clinical and laboratory professionals in order to ensure their correct interpretation.

A síndrome do anticorpo antifosfolípide (SAAF) é uma trombofilia autoimune adquirida, caracterizada pela presença de uma família heterogênea de anticorpos que se ligam a proteínas plasmáticas com afinidade, por superfícies fosfolipídicas. As duas principais proteínas-alvo dos anticorpos antifosfolípides (AAF) são a protrombina e a β2-glicoproteína 1 (β2GP1). A SAAF está associada a um estado protrombótico e é clinicamente caracterizada pela ocorrência de trombose arterial, venosa ou microvascular ou perda fetal recorrente. O diagnóstico da SAAF é baseado em um conjunto de critérios clínicos e na detecção plasmática de anticoagulante lúpico (AL), anticorpo anticardiolipina (ACA) ou antiβ2GP1. Embora os testes laboratoriais sejam de fundamental importância para o diagnóstico da SAAF, eles apresentam limitações associadas à robustez, à reprodutibilidade e à padronização. A padronização de testes diagnósticos para a pesquisa de AAF tem sido um desafio, pois uma variedade de resultados pode ser obtida utilizando diferentes kits comerciais e técnicas in-house. Um aumento da sensibilidade dos kits de ELISA para a detecção do ACA contribuiu efetivamente para o diagnóstico da SAAF. No entanto, a falta de especificidade, associada a um número elevado de resultados falso-positivos, é um desafio clínico e laboratorial, uma vez que tais resultados podem levar a decisões clínicas erradas, como a prescrição de anticoagulante oral, levando ao risco de hemorragia. Além disso, os clínicos muitas vezes não estão familiarizados com esses testes e têm dificuldade em interpretá-los, sendo necessária a interação da clínica e dos profissionais do laboratório para assegurar sua correta interpretação.

Anticardiolipin antibodies and lupus anticoagulants among women undergoing in vitro fertilization in Jamaica / Anticuerpos anticardiolipinas y anticoagulantes lúpicos entre mujeres a las que se les realiza FIV en Jamaica

OBJECTIVE: The aims of this study were to evaluate the effect of anticardiolipin antibody (aCL) and lupus anticoagulant (LA) on the outcome of the in vitro ferlitization (IVF) cycles and to determine the prevalence of these antibodies in infertile women seeking IVF in Jamaica. METHODS: A retrospective cohort study was performed to determine if screening patients for aCL and LA had any significant impact on the outcome of the IVF process. Each patient's hospital record, between March 2000 and March 2010, was collected and the relevant data extracted. RESULTS: The prevalence of aCL in this cohort of Jamaican women was moderate/high positive 3.88%, low positive 0.68% and those with negative aCL results 95.4%. The prevalence of women who were LA positive was 4.1% and 0.9% of the women were positive for both LA and aCL. Of the patients who were LA and/or aCL positive, eight out of 30 patients (26.7%) had a positive pregnancy test in comparison to 61 out of 181 patients (33.7%) who were LA and/or aCL negative (p = 0.5787). CONCLUSION: The prevalence of positive aCL and/or lA in infertile women seeking IVF in Jamaica is 7.76%. The presence of these antibodies did not affect the pregnancy rate of these women nor did it demonstrate an increased risk for IVF cycle cancellation or ovarian hyperstimulation syndrome. Screening women undergoing IVF for these antibodies is not justified.

OBJETIVO: Los objetivos de este estudio fueron evaluar el efecto del anticuerpo anticardiolipina (aCL) y el anticoagulante lúpico (LA) sobre el resultado de los ciclos de la fertilización en vitro (FIV), así como determinar la prevalencia de estos anticuerpos en mujeres estériles que buscan tratamiento de FIV en Jamaica. MÉTODOS: Se realizó un estudio de cohorte para determinar si el tamizaje de pacientes para detectar el anticuerpo anticardiolipina y el anticoagulante lúpico tenía un impacto significativo en el resultado del proceso de FIV. Se obtuvieron las historias clínicas hospitalarias de cada una de las pacientes, entre marzo de 2000 y marzo de 2010, y se extrajeron los datos pertinentes. RESULTADOS: La prevalencia de aCL en esta cohorte de mujeres jamaicanas fue 3.88% moderada/alta positiva, 0.68% positiva baja, y aquellas con resultados negativos de aCL, 95.4%. La prevalencia de mujeres con resultados de anticoagulante lúpico positivos fue 4.1%, y 0.9% de las mujeres resultaron positivas con respecto tanto al LA como al aCL. De las pacientes que fueron positivas al LA y/o al aCL, ocho de cada 30 pacientes (26.7%) tuvieron una prueba de embarazo positiva, en comparación con 61 de cada 181 pacientes (33.7%) negativas al LA y/o al aCL (p = 0.5787). CONCLUSIÓN: La prevalencia de resultados positivos en relación con anticuerpos anticardiolipinas y/o anticoagulantes lúpicos en mujeres estériles que buscan FIV en Jamaica es 7.76%. La presencia de estos anticuerpos no afectó la tasa de embarazo de estas mujeres, ni mostró un aumento de riesgo de la cancelación del ciclo FIV, o riesgo de síndrome de hiperestimulación ovárica. El tamizaje en busca de estos anticuerpos en mujeres que buscan tratamiento de FIV, no está justificado.

Hyperhomocysteinemia in HIV-infected individuals: correlation of a frequent prothrombotic factor with CD4+ Cell count

This study was aimed at providing an analysis of the correlation between CD4/CD8 counts and some coagulation factors in HIV-Positive Iranian patients. A case-control study on 58 HIV-infected patients and control group [58 healthy individuals]. Patients and controls were matched for sex and age. In this study, several blood parameters were measured in 58 HIV-infected patients and the controls. Laboratory data were then measured including hemoglobin, platelets, homocysteine, serum levels of IgM and IgG antiphospholipid antibodies [aPL], IgM and IgG anticardiolipin antibotdies [aCL], and CD4[+] and CD8[+] cell count. The HIV-infected patients, compared to healthy controls, showed a significant decline in platelets, CD4 count and CD8 count [p<0.0001], and an increase of homocysteine [p<0.0001] and IgG aPL levels [p<0.0001]. No statistical difference was found between patients with CD4 count 200 in the evaluated variables. The results showed that thrombophilic abnormality in the form of hyperhomocysteinemia is more frequent in HIV-infected patients and should be considered by clinicians in view of an early diagnosis of the hypercoagulability state to prevent thrombotic complications

Clinical and serological risk factors of systemic lupus erythematosus outcomes during pregnancy

SLE is an important risk factor for mother and fetus during pregnancy. To identify clinical and serological risk factors that may cause poor maternal and fetal outcomes in pregnant systemic lupus erythematosus [SLE] patients. Forty selected SLE pregnant women [group A] versus 35 non-pregnant SLE patients [group B]. SLE disease activity index [SLEDAI] and flares were evaluated for both groups. Laboratory investigations included double stranded DNA, anticardiolipin antibodies [aCL], and complements [C3 and C4]. SLE pregnant patients were followed up in the second and third trimesters by ultrasonography and fetal Doppler were done to assess fetal outcome. Risk factors for poor maternal and fetal outcome were recorded. SLEDAI was increased in both groups more in group A. Lupus flares were increased during pregnancy as it occurred in [62.5%] of group A compared to [37.14%] in group B where severe flares were more frequent in group A. Gestational hypertension and active SLEDAI were found statistically significant for poor maternal outcome. Fetal outcome included full term 37.5%, prematurity 25%, intra-uterine growth retardation [IUGR] 22.5%, stillbirth 12.5%, abortion 7.5% and congenital heart block [CHB] 2.5%. Factors significantly associated with poor fetal outcome were severe flares and active renal disease where fetal loss significantly associated with aCL antibodies. Full term was more common in patients with no flares. These data demonstrate that pregnancy in SLE patients should be considered as a high-risk pregnancy and conception should be planned during a quiescent period. Close monitoring for optimal disease control of flares, lupus nephritis, gestational hypertension and aCL antibodies is recommended

Prolactina, estradiol e anticorpos anticardiolipina em amostra de mulheres pré-menopáusicas com lúpus eritematoso sistêmico: estudo-piloto / Prolactin, estradiol and anticardiolipin antibodies in premenopausal women with systemic lupus erythematosus: a pilot study

INTRODUÇÃO: O lúpus eritematoso sistêmico (LES) é uma doença autoimune com maior prevalência em mulheres. A maior incidência ocorre durante os anos reprodutivos, sugerindo que o estradiol tenha influência na apresentação clínica do LES. Anticorpos anticardiolipina (ac-ACL) estão relacionados com a síndrome do anticorpo antifosfolipídeo (SAF), mas podem estar presentes em pacientes com LES sem SAF, sendo relacionados com risco cardiovascular e nefrite. OBJETIVO: Determinar se a presença de ac-ACL está associada a alterações hormonais em uma amostra de mulheres com LES. MÉTODOS: Foram avaliadas 47 mulheres com LES de acordo com os critérios do American College of Rheumatology, com idade média de 30,8 ± 8,12 anos. Nenhuma fazia uso de anticoncepcional hormonal, e a atividade do LES foi estimada pelo índice de atividade da doença (SLEDAI). As pacientes foram estratificadas de acordo com a presença ou não de ac-ACL, e os níveis séricos de estradiol e prolactina foram determinados. RESULTADOS: Nove (19,1 por cento) das 47 pacientes tiveram ac-ACL positivos. Idade, tempo de doença e o SLEDAI foram similares entre os grupos. No entanto, a mediana do estradiol foi menor no grupo com ac-ACL positivo [46,8 (21,0-72,1) pg/mL] com relação ao grupo com ac-ACL negativo [122,3 (64,8-172,7) pg/mL, P = 0,004]. CONCLUSÃO: Estes resultados sugerem, pela primeira vez, uma associação inversa entre ac-ACL e níveis de estradiol em pacientes pré-menopáusicas com LES. Considerando que tanto níveis reduzidos de estradiol endógeno quanto presença de ac-ACL estão associados a aterosclerose, este achado pode ser clinicamente relevante em predizer risco cardiovascular e/ou desenvolvimento de SAF no LES.

INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease, with higher prevalence in women. An incidence peak occurs during the reproductive years, suggesting that estradiol may play a role in the clinical presentation of SLE. Anticardiolipin antibodies (ACA) are associated with antiphospholipid antibody syndrome (APLS), but can be found in patients with SLE without APLS, and relate to cardiovascular risk and nephrite. OBJECTIVE: This study aimed at assessing whether the presence of ACA is associated with hormonal changes in a sample of women with SLE. METHODS: Forty-seven women diagnosed with SLE according to the American College of Rheumatology criteria, aged 30.8 ± 8.12 years, were evaluated. None was on hormonal contraception, and their SLE activity was estimated using the SLE Disease Activity Index (SLEDAI). Patients were stratified, according to the presence or absence of ACA, and estradiol and prolactin levels were measured. RESULTS: Nine (19.1 percent) of 47 patients were positive for ACA. No differences were found between groups concerning age, duration of disease, and SLEDAI. In contrast, the median estradiol level was lower in the ACA-positive group [46.8 (21.0-72.1) pg/mL] than in the ACA-negative group [122.3 (64.8-172.7) pg/mL, P = 0.004]. CONCLUSION: These results suggest, for the first time, an inverse association between ACA and estradiol levels in premenopausal SLE patients. Considering that both lower endogenous estradiol levels and ACA positivity are related to atherosclerosis, our finding may be clinically relevant in predicting cardiovascular risk and/or APLS development in SLE.

Úlceras de pernas e anticorpos anticardiolipinas / Leg ulcers and anticardiolipin antibodies

Fenômenos pró-trombóticos são descritos em úlceras de perna de diferentes etiologias. Neste trabalho, procurou-se verificar a prevalência de anticorpos anticardiolipina nestes pacientes. Para isso, estudaram-se 151 pacientes com úlcera de pernas e 150 controles, sendo obtidos dados clínicos e títulos de anticorpos anticardiolipina. Os anticorpos anticardiolipina foram detectados em 7,2 por cento do grupo úlcera e 1,3 por cento do grupo controle (p=0.01), todavia, as características clínicas não foram diferentes nos pacientes com e sem anticorpos anticardiolipina.

Prothrombotic phenomena are described in leg ulcers of different etiologies. This work attempts to verify the prevalence of anticardiolipin antibodies in such patients. For this purpose, 151 patients with leg ulcers and 150 control patients were studied and it was obtained clinical data and anticardiolipin antibodies titers. Anticardiolipin antibodies were detected in 7,2 percent of the patients from the ulcer group against 1.3 percent of the patients in the control group (p=0.01). However, clinical characteristics were not different in patients with and without anticardiopilin antibodies.

Serum COMP and their correlations with various disease parameters in patients with systemic lupus erythematosus and osteoarthritis

The cartilage oligomeric matrix protein [COMP] is a glycoprotein, which occurs mainly in an articular cartilage. The amount of this protein increases under the influence of cytokines and growth factors. As a result of various diseases that cause damage to cartilage, fragments of matrix protein are released into synovial fluid and then into blood. The assessment of matrix protein level in serum, for example COMP, permits the establishment of the degree of cartilage damage in inflammatory joint diseases, and permits observation of the effectiveness of the treatment. To assess serum COMP level, as a marker for cartilage degradation, in SLE and OA patients and to find a correlation between serum COMP level and other markers as well as activity of disease, disease duration and the age of the patients. Blood was collected from 40 systemic lupus erythematosus [SLE] patients group I, [the patients were further subdivided into two subgroups, group [Ia] comprised 20 SLE patients received 1 g IV methylprednisolone [MP] daily for three successive days, group [Ib] comprised 20 SLE patients did not receive IV methylprednisolone [MP]], and from 20 patients with knee osteoarthritis [OA] group II who constituted the control group. Serum COMP level was determined using an inhibition enzyme-linked immunosorbent assay [ELISA]. The measured values of the serum COMP level in SLE patients ranged from 1.32 to 1.71 microg/ml with a mean of 1.51 +/- 0.13 microg/ml in group [Ia], and ranged from 2.43 to 3.56 microg/ml with a mean of 2.86 +/- 0.31 microg/ml in group [Ib]. While in OA group [II] the value of serum COMP ranged from 0.97 to 2.65 microg/ml with a mean of 1.25 +/- 0.37 microg/ml. We found significantly elevated COMP levels in the SLE group [Ib] compared to the SLE group [Ia] patients and OA group [II] [p < 0.001]. We found a statistically significant positive correlations with the number of tender joints [correlation coefficient Pearson's: r = 0.45, p < 0.01], the number of swollen joints [r = 0.55, p < 0.001], SLAM value [r = 0.56, p < 0.001]. A significant positive correlation was found between serum COMP level and the ESR value in the first hour [r = 0.35, p < 0.001]. While the serum COMP level was independent of the patients' age [r = 0.04, p = NS], disease duration [r = -0.03, p = NS] and morning stiffness duration [r = -0.05, p = NS]. Also a Negative correlation was found between the serum COMP level and haemoglobin value [r = -0.11, p = NS]. As regards the OA group, no correlation was found between the serum COMP level and patients' age [r = -0.05, p = NS] and disease duration [r = 0.24, p = NS]. There were positive correlations between serum COMP and WOMAC index score for the lower limbs [r = 0.64, p < 0.05]. The serum COMP level can be an important marker of disease activity and cartilage destruction in SLE and OA Patients, and that serum levels of COMP can be used as a parameter for monitoring the therapy response in SLE patients undergoing an intravenous bolus steroid therapy

Clinical Implications of Elevated Antiphospholipid Antibodies in Adult Patients with Primary Immune Thrombocytopenia

BACKGROUND/AIMS: Antiphospholipid antibodies (aPL) have been detected in various proportions of patients with primary immune thrombocytopenia (ITP), but the clinical significance of this is debatable. The present study aimed to determine the frequency and clinical implications of elevated aPL in adult patients with ITP. METHODS: We prospectively studied newly diagnosed adult patients with ITP who were enrolled between January 2003 and December 2008 at Chungnam National University Hospital. They were evaluated for the presence of lupus anticoagulant (LA) and anticardiolipin antibodies (aCL) at diagnosis and were followed for the development of thrombosis. RESULTS: Seventy consecutive patients with ITP (median age, 48 years; range, 18 to 79) were enrolled. Twenty patients (28.5%) were positive for aPL at the time of diagnosis: aCL alone in 15 (75%), aCL and LA in two (10%), and LA alone in three (15%). Patients who had platelet counts < 50,000/microL were administered oral prednisolone with or without intravenous immune globulin. No difference was found between the aPL-positive and -negative groups regarding gender, initial platelet count, and response to the therapy. After a median follow-up of 20 months (range, 2 to 68), two of 20 patients who were aPL-positive (10%) developed thrombosis, whereas no thrombotic event was found among those who were aPL-negative. CONCLUSIONS: Our data suggest that aPL levels should be determined at the initial presentation of ITP and that patients found to be aPL-positive should receive closer follow-up for thrombotic events.

Estudo de associação entre anticorpos anticardiolipinas e fenômenos vasculares periféricos em pacientes com esclerodermia sistêmica / Study about the association between anticardiolipin antibodies and peripheral vascular phenomena in patients suffering from systemic scleroderma

Isquemia é comum em esclerodermia sistêmica e é causada por vasoespasmo e trombose. As autoras analisaram a associação de eventos vasculares periféricos e anticorpos anticardiolipinas (aCl) em 54 esclerodérmicos. Em 100 por cento deles existia Raynaud; 59,2 por cento apresentaram cicatrizes estelares; 43,3 por cento, telangiectasias; 14,8 por cento, fenômenos tromboembólicos periféricos. ACl IgG foram positivos em 9,2 por cento dos casos e o IgM, em 7,4 por cento. Fenômenos embólicos periféricos estão associados a aCl IgG (p=0,03), não se encontrando associação com demais manifestações.

Ischemia is common in systemic scleroderma and it is caused by vasospasm and thrombosis. In the present study we analyzed the association of peripheral vascular events and anticardiolipin (aCl) antibodies in 54 patients suffering from systemic scleroderma. The results showed that 100 percent of the patients presented Raynaud; 59.2 percent presented digital micro scars; 43.3 percent, presented teleangiectasies and 14.8 percent, presented peripheral thromboembolism. ACl IgG were positive in 9.2 percent and IgM, in 7.4 percent. Peripheral tromboembolic phenomena had a positive association with aCl IgG (p=0.03). No other associations were found.

Pregnancy outcome in women with antiphospholipid syndrome on low-dose aspirin and heparin: a retrospective study

This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of 64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications. There were no significant differences in antenatal and maternal complications between the groups. However, there were significant differences in mean anticardiolipin IgG antibody levels. Aspirin alone or in combination with heparin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage

Prevalence and Clinical Associations of Lupus Anticoagulant, Anticardiolipin Antibodies, and Anti-beta2-glycoprotein I Antibodies in Patients with Systemic Lupus Erythematosus / 대한진단검사의학회지

BACKGROUND: The presence of antiphospholipid antibodies (aPLs) is associated with the clinical features of antiphospholipid syndrome (APS), which comprises venous and arterial thrombosis and pregnancy loss, and systemic lupus erythematosus (SLE). The prevalence of aPLs has been reported to be different in patient populations affected by either of these conditions. We performed a retrospective study to evaluate the prevalence and clinical associations of aPLs, including lupus anticoagulant (LAC), anticardiolipin (aCL), and anti-beta2-glycoprotein I antibodies (anti-beta2-GPI) in a cohort of Korean patients with SLE. METHODS: This study included samples from 88 SLE patients for whom aPL testing had been advised between June 2006 and July 2009 at the Dong-A University Hospital. Serum and plasma samples were tested for LAC, aCL (IgG, IgM), and anti-beta2-GPI (IgG, IgM) antibodies. Clinical data from patients were obtained from a review of medical records. RESULTS: LAC was the most common (34.1% of total patients, 30/88) antibody, followed by IgM aCL (31.8%, 28/88), IgG aCL (18.2%, 16/88), and IgM and IgG anti-beta2-GPI (both 5.7%, 5/88 each). Positivity for LAC was strongly associated with venous/arterial thrombosis (P=0.002). CONCLUSIONS: LAC was the most common antibody detected in Korean SLE patients and is shown to have a significant association with the presence of venous/arterial thrombosis. The measurement of LAC may be clinically useful in identifying patients with SLE who are at a high risk for venous/arterial thrombosis.

Contagem de plaquetas e caracterização clínica de úlceras de perna anticardiolipinas positivas / Platelet count and clinical profile of anticardiolipin positive leg ulcers

OBJETIVO: Estudar a prevalência de anticorpos anticardiolipinas em pacientes com úlceras venosas, diabéticas e arteriais e verificar se a contagem de plaquetas, antecedentes obstétricos e de trombose venosa profunda e achados de livedo reticularis ao exame físico servem como marcadores para os casos positivos. MÉTODOS: Estudaram-se 151 pacientes com úlcera de perna (81 com úlceras venosas, 50 com úlceras diabéticas e 20 com úlceras arteriais) e 150 controles. Pesquisou-se, nos dois grupos, a presença de anticorpos anticardiolipina IgG e IgM e contagem de plaquetas. No grupo úlcera foram coletados dados de antecedentes de trombose venosa profunda e de abortamentos e os pacientes foram examinados para presença de livedo reticularis. Os dados obtidos foram agrupados em tabelas de frequência e contingência utilizando-se dos testes de Fisher e qui-quadrado para variáveis nominais e de Mann-Whitney e Kruskall-Wallis para as numéricas. Adotou-se significância de 5 por cento. RESULTADOS: Encontrou-se prevalência de anticorpos anticardiolipina de 7.2 por cento (n=12) no grupo com úlceras e de 1.3 por cento (n=2) no controle (p=0.01). As úlceras de perna anticardiolipinas positivas não diferiram daquelas sem anticardiolipinas quanto ao gênero do paciente (p=0.98) e história de trombose prévia (p=0.69), abortamentos anteriores (p=0.67) e contagens de plaquetas (p=0.67). Só dois pacientes tinham livedo reticularis não permitindo inferências estatísticas a respeito deste dado. CONCLUSÃO: Existe aumento de prevalência de anticorpos anticardiolipinas nos portadores de úlceras de perna em relação à população geral. As características clínicas das úlceras anticardiolipinas positivas e a contagem de plaquetas não auxiliam na identificação desses pacientes.

OBJECTIVE: To study the prevalence of anticardiolipin antibodies in patients with venous, diabetic and arterial leg ulcers and to verify if platelet count, previous history of venous thrombosis, obstetrical history and the finding of livedo reticularis are markers of this autoantibody positivity. METHODS: 151 patients with leg ulcer (81 with venous, 50 with diabetic and 20 with arterial ulcers) and 150 controls were included. In both groups search for the presence of IgG and IgM anticardiolipin and platelet count was done. In the leg ulcer group demographic data, obstetrical history, previous history of venous thrombosis as well as presence of livedo reticularis by physical examination were pointed out. Data was grouped in contingency and frequency tables and the tests of Fisher and chi-squared were used for nominal variables and Mann Whitney and Kruskall Wallis for numerical variables. The adopted significance was of 5 percent. RESULTS: It was found an anticardiolipin prevalence of 7.2 percent (n=12) in the leg ulcer group and of 1.3 percent (n=2) in the control group (p=0.01). Leg ulcer patients with anticardiolipin did not differ from those without it in gender (p=0.98), previous history of venous thrombosis (p=0.69), previous history of abortions (p=0.67) and platelet count (p=0.67). Only two patients had livedo reticularis which precluded any conclusion on this data. CONCLUSION: There is an increased prevalence of anticardiolipin antibodies in the general population with leg ulcers. Clinical characteristics of ulcers as well as platelet count do not help in the identification of these patients.

Anticorpos anticardiolipinas em úlceras de perna / Anticardiolipin antibodies in leg ulcers

Objetivo: Verificar a prevalência de anticorpos anticardiolipinas IgG e IgM em pacientes com úlcera de perna e se os seus portadores podem ser identificados clinicamente. Métodos: Estudaram-se 151 pacientes com úlcera de perna (81 venosas, 50 diabéticas e 20 arteriais) e 150 controles. Pesquisou-se, nos dois grupos, a presença de anticorpos anticardiolipina IgG e IgM pelo método de ELISA. No grupo úlcera foram coletados dados demográficos dos pacientes, de tamanho e número de úlceras e gravidade da dor medido por escala visual analógica. Os dados obtidos foram agrupados em tabelas de frequência e contingência. Adotou-se significância de 5%. Resultados: Encontrou-se prevalência de anticorpos anticardiolipina de 7.2% (n=12) no grupo com úlceras e de 1.3% (n=2) no controle (p=0.01). Comparando-se a prevalência dos anticorpos anticardiolipina nos diferentes tipos de úlcera verificou-se aumento nas de origem venosa (p=0.02) e diabéticas (p=0.01), mas não nas arteriais (p=0.31) em relação à população controle. As úlceras de perna anticardiolipinas positivas não diferiram daquelas sem anticardiolipinas quanto a tamanho da ferida (p=0.6); gravidade da dor (p=0.67), número médio de úlceras (p=0.38), tempo de duração de doença (p= 0.59), gênero do paciente(p=0.98) e história de trombose prévia (p=0.69). Conclusão: Existe aumento de prevalência de anticorpos anticardiolipinas nos portadores de úlceras de perna venosas e diabéticas, mas não nas arteriais. As características clínicas das úlceras anticardiolipinaspositivas não auxiliam na identificação desses pacientes.

Objective: To verify the prevalence of IgG and IgM anticardiolipin antibodies in patients with leg ulcer (venous, arterial and diabetic) and if these patients can be identified by clinical means. Methods: A serie of 151 patients with leg ulcer (81 venous, 50 diabetic and 20 arterial ulcers) and 150 controls were studied. In both groups it was searched the presence of IgG and IgM anticardiolipin by the ELISA method. In the leg ulcer group demographic data were obtained, data on the leg ulcer size and number as well as pain severity measured by an analogical visual scale. In statistic analysis, the adopted significance was of 5%. Results: It was found an anticardiolipin prevalence of 7.2% (n=12) in the leg ulcers group and of 1.3% (n=2) in the control group (p=0.01). Comparing the different ulcer types with control population, it was found that there was an increase in anticardiolipin antibodies in venous (p=0.02), and diabetic (p=0.01) but not in arterial ulcers (p=0.31). Leg ulcer patients with anticardiolipin did not differ from those without it in gender (p=0.98); ulcer size (p=0.6); pain severity (p=0.67), mean number of ulcers (p=0.38), mean disease duration time (p= 0.59) and previous history of venous thrombosis (p=0.69). Conclusion: There is an increased prevalence of anticardiolipin antibodies in patients with venous leg ulcers anddiabetic ulcers but not in those of arterial origin. Clinical characteristics of ulcers do not help in the identification of these patients.

Anti-cardiolipin antibodies and cardiac involvement in systemic lupus erythematosus

To study anticardiolipin antibodies [aCL] in blood and clarify their possible relation to cardiac involvement in patients with systemic lupus erythematosus [SLE]. Twenty SLE patients and twelve healthy persons, as a control group, were included into this study. All patients were subjected to full clinical assessment and laboratory investigations. aCL antibodies IgG were measured in patients and controls using the enzyme-linked immunosorbent assay [ELISA] technique and their correlations with disease activity parameters were studied. SLE patients were divided according to the presence of aCL antibodies into two groups: first group of 9 patients with negative aCL antibodies and second of 11 patients with positive aCL antibodies. A highly statistically significant difference [p<0.001] was found between aCL antibodies IgG level in SLE patients vs. control group, A statistical significant difference was also observed [p<0.05] in aCL antibodies between both groups of SLE patients in relation to clinical data, laboratory data and disease activity. On echocardiography, there was a significant correlation [p<0.05] between the presence of aCL antibodies and the occurrence of mitral regurge in aCL positive patients, while there was no significant correlation with other echo parameters. There was an association between the presence of aCL antibodies and cardiac abnormalities in SLE patients on echocardiographic examination especially valvular lesions [regurgitation more than stenosis]. This suggests that aCL antibodies may play a role in the pathogenesis and the severity of cardiac lesions. Also; there was an association between echocardiographic changes as well as high serum levels of aCL antibodies with SLE disease activity

Prevalence of Antiphospholipid antibodies in Syrian patients with thrombosis

Antiphospholipid antibodies [aPL] are a heterogeneous family of antibodies associated with thrombosis and other complications. To study the prevalence of aPL in patients with thrombosis at Aleppo University Hospitals, Syria. One hundred and fifty-seven patients with venous and arterial thrombosis and 63 healthy controls were studied. Anticardiolipin antibodies [aCL] and Lupus anticoagulant [LA] were determined. Thirty-four out of 157 [21.7%] patients with thrombosis had some type of aPL. aPL was also found in four healthy subjects [4/63=6.3%]. Eighteen patients [11.5%] were positive for LA, 20 [12.7%] for aCL antibodies and 4 [2.6%] were positive for more than one aPL. Patients without risk factors for thrombosis and having positive aPL were 23/34 [67.7%]. Fourteen out of 78 [17.9%] patients with arterial thrombosis, and 20/79 [25.3%] with venous thrombosis were positive for at least one aPL. Our study showed a significant prevalence of aPL in patients with thrombosis. It seems that aPL is a risk factor for venous and arterial thrombosis, especially in patients with no conventional risk factors

Antiphospholipid antibodies in Brazilian hepatitis C virus carriers

Hepatitis C, a worldwide viral infection, is an important health problem in Brazil. The virus causes chronic infection, provoking B lymphocyte dysfunction, as represented by cryoglobulinemia, non-organ-specific autoantibody production, and non-Hodgkin's lymphoma. The aim of this research was to screen for the presence of antiphospholipid autoantibodies in 109 Brazilian hepatitis C virus carriers without clinical history of antiphospholipid syndrome. Forty healthy individuals were used as the control group. IgA, IgG, and IgM antibodies against cardiolipin and ß2-glycoprotein I were measured with an enzyme-linked immunosorbent assay, using a cut-off point of either 20 UPL or 20 SBU. While 24 (22.0 percent) hepatitis C carriers had moderate titers of IgM anticardiolipin antibodies (median, 22.5 MPL; 95 percentCI: 21.5-25.4 MPL), only three carriers (<3 percent) had IgG anticardiolipin antibodies (median, 23 GPL; 95 percentCI: 20.5-25.5 GPL). Furthermore, IgA anticardiolipin antibodies were not detected in these individuals. Male gender and IgM anticardiolipin seropositivity were associated in the hepatitis C group (P = 0.0004). IgA anti-ß2-glycoprotein-I antibodies were detected in 29 of 109 (27.0 percent) hepatitis C carriers (median, 41 SAU; 95 percentCI: 52.7-103.9 SAU). Twenty patients (18.0 percent) had IgM anti-ß2-glycoprotein I antibodies (median, 27.6 SMU; 95 percentCI: 23.3-70.3 SMU), while two patients had IgG antibodies against this protein (titers, 33 and 78 SGU). Antiphospholipid antibodies were detected in only one healthy individual, who was seropositive for IgM anticardiolipin. We concluded that Brazilian individuals chronically infected with hepatitis C virus present a significant production of antiphospholipid antibodies, mainly IgA anti-ß2-glycoprotein I antibodies, which are not associated with clinical manifestations of antiphospholipid syndrome.

Prothrombin gene G 20210 a mutation in patients with acute deep venous thrombosis

Deep venous thrombosis [DVT] is an interaction between hereditary and acquired factors. Prothrombin gene mutation is one of these hereditary risk factors that may cause DVT through elevation of the Prothrombin level and therefore, requires special attention. In this study we tried to have an idea about frequency of this gene mutation in patients with DVT. Prothrombin gene mutation was looked for in forty Warfarin-Resistances DVT patients. The results were compared to another forty Warfarin-Sensitive DVT patients and thirty healthy blood donors. In addition blood samples were assessed for the levels of protein C, protein S, antithrombin III and anticardiolipin antibodies. Recurrent DVT and positive family history were more frequent in the Warfarin-Resistance group. Prothrombin gene mutation was found in DVT patients as well as healthy controls, but with different percentages. The higher frequency of this gene mutation in Warfarin-Resistance individuals may confirm its mechanism in causing DVT. This study supports that Prothrombin gene mutation is present in our population, especially DVT patients. The study also suggests that patients with Warfarin-Resistance should be tested for the presence of this gene mutation

Paraoxonase 1 activity and genotyping in systemic lupus erythematosus and their relationships with cardiovascular complications

Systemic lupus erythematosus [SLE] is characterized by an enhanced risk of atherosclerosis and cardiovascular diseases [CVD]. Human serum paraoxonase 1 [PON1], an antioxidant enzyme closely associated with high density lipoprotein [HDL], has been implicated in the prevention of low density lipoprotein [LDL] oxidation, and these may provide HDL-associated protection against atherosclerosis. Our objective was to evaluate PON1 activity and genotypes in SLE patients and their relationships to cardiovascular complications and some other risk factors of cardiovascular diseases in those patients. Thirty SLE patients, subdivided into patients with CVD and without CVD, and fifteen matched healthy control subjects were studied. Laboratory investigations included lipid profile, lupus anticoagulants [LA], anticardiolipin antibodies [aCL]. PON1 activity was determined by paraoxon substrate. PON1 genotyping was conducted by PCR amplification, followed by polymorphism-specific restriction enzyme digestion and gel electrophoresis. Our study revealed that PON1 activity was significantly decreased in SLE patients groups compared to controls and in SLE patients with CVD compared to those without CVD [p<0.001]. PON1 activity was significantly negatively correlated with total cholesterol, LDL-C and LDL-C/HDL-C ratio, positively correlated with HDL-C but not significantly correlated with triglycerides, disease activity, LA or a CL antibodies. As regard PON1 192 gene polymorphism, there was significant increase in B allele frequency in SLE patients with CVD compared to those without CVD and control groups, while no significant difference was found between SLE patients without CVD and control group. As regard PON1 55 gene polymorphism, there was no significant difference in genotype distribution or allele frequency between the three groups. The Odds ratio of development of CVD in SLE patients who carry PON1 192B allele was 6 [95% CI 1.2-30.7, p<0.05]. PON1 activity determined by paraoxon substrate was significantly higher in BB and LL, intermediates in AB and LM, and lower in AA and MM genotypes

Thrombophilia and pregnancy outcomes

Pregnancy complications are still a challenge for physicians, because knowledge of pathomechanisms and prophylactic measures is still limited. In recent years thrombophilia as a risk factor for pregnancy complications has gained much attention in the scientific community. To study the rate of thrombophillia gene in cases with recurrent abortion. In the period between January 2006 and May 2007, 40 consecutive patients with a history of recurrent failed IVF and abortion, defined as fetal loss before 16 weeks' gestational age, were screened by the following tests: Molecular diagnosis of 11 thromobophilia gene mutation, ACL IgG and IgM. PtC, PtS. ATIII and Lupus anticoagulants. 40 patients were included in this study and the following data was recorded: All cases were negative to protein C, S and anti T Ill. One case showed positive anti cardiolipin Ig M-3 cases positive for Lupus anticoagulant, all the cases were positive for multiple thrombophillia genes. The observed rate of successful pregnancies of women treated with aspirin, who had mild thrombophilia and a history of a single abortion, is much lower than it would haye been expected from patient treated with combined therapy